Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | E160K |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | FGFR2 E160K lies within Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). E160K results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 E160K FGFR2 mutant FGFR2 exon5 FGFR2 E160K |
Transcript | NM_000141.5 |
gDNA | chr10:g.121551436C>T |
cDNA | c.478G>A |
Protein | p.E160K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144917.1 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
XM_017015921.3 | chr10:g.121564535C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001144916.2 | chr10:g.121520095C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
XM_006717710.5 | chr10:g.121564535C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001320658.2 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001320658.1 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
XM_017015920.3 | chr10:g.121564535C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
XM_006717708.4 | chr10:g.121564535C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001144918.2 | chr10:g.121520095C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
NM_001144917.2 | chr10:g.121551436C>T | c.478G>A | p.E160K | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|